Evaluation of a commercially available Zika virus IgM ELISA: specificity in focus.
Zika virus (ZIKV), an emerging arbovirus, has become the center of attention since it was linked to congenital abnormalities. Given the overlapping clinical picture of ZIKV disease with other infectious diseases and as an exigent public health matter, timely and reliable diagnosis of ZIKV infection is crucial. We evaluated the performance of a commercially available NS1-based ZIKV IgM ELISA. Our results showed suboptimal sensitivity within the first 5 days after onset while specificity remained robust.